Big Penis Male Sexual Stimulant Contains Hidden Drug Ingredient

The Food and Drug Administration (FDA) is advising consumers not to purchase or use Big Penis Male Sexual Stimulant, a product promoted for sexual enhancement. This product was identified by FDA during an examination of international mail shipments.To get more news about vigrx oil, you can visit vigrxplus-original.com official website.
FDA laboratory analysis confirmed that Big Penis Male Sexual Stimulant contains sildenafil, the active ingredient in the FDA-approved prescription drug Viagra, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.

Note: This notification is to inform the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals. These products are typically promoted for sexual enhancement, weight loss, and body building and are often represented as being “all natural.” FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. Consumers should exercise caution before purchasing any product in the above categories.

The FDA has approved the first prescription drug that has been dubbed “female viagra” or the “little pink pill.” But for now, it’s only available in the states.

A sex therapist says this type of medication has been a long time coming but even if it does make it to Canada there are no guarantees it would be covered by OHIP.

It’s called Flibanserin also known as Addyi.

For more than 15 years, ads have pushed pills for men such as viagra to treat erectile dysfunction. Experts say calling the new drug “female Viagra” is a misnomer, because Viagra does not induce sexual desire; it just treats a physical problem.

More than 1,300 Canadian women have been involved in tests of Flibanserin.

The drug was rejected by the FDA in 2010, and again in 2013, over concerns about side effects like dizziness, nausea and sleepiness.